Abstract Gastrointestinal follicular lymphoma (GI-FL) is a relatively rare disease, accounting for only 1%-3.6% of gastrointestinal non-Hodgkin's lymphoma. Although the duodenum and terminal ileum are considered to be the most common sites of origin, the development of wireless capsule endoscopy and double-balloon enteroscopy has increased the detection of GI-FL in every part of the small intestine. Approximately 70% of patients with GI-FL are estimated to have multiple lesions throughout the entire gastrointestinal tract. FL is a low-grade lymphoma that usually develops very slowly. If the lymphoma causes no symptoms, immediate treatment may not be necessary. Standard therapy has not yet been established for GI-FL, but chemotherapy, radiotherapy, monoclonal antibody therapy, or a combination of these therapies, is sometimes performed based on the therapeutic regimens for nodal FL. Regimens including conventional chemotherapy with rituximab, which achieve high response rates in nodal FL, are commonly used for GI-FL. The long-term clinical outcome of GI-FL is unclear. The results of a few series on the long-term outcomes of patients with GI-FL treated with conventional therapy indicate a median relapse-free time ranging from 31 to 45 months. On the other hand, in patients with GI-FL who were followed without treatment, the median time to disease progression was 37.5 months. Thus, whether to initiate aggressive therapy or whether to continue watchful waiting in patients with GI-FL is a critically important decision. Ongoing research on biomarkers to guide individualized GI-FL therapy may provide invaluable information that will lead to the establishment of a standard therapeutic regimen.
Introduction
Follicular lymphoma (FL) is one of the most common subtypes of non-Hodgkin's lymphoma (NHL) in the Western world, although its incidence may be lower in some parts of the world such as Asia [1] . Most cases of FL are initially detected in the lymph nodes, and involvement of extranodal sites usually occurs only as a result of disseminated nodal disease [2] . The gastrointestinal (GI) tract is the most common site of extranodal NHL, accounting for 30%-40% of all primary extranodal NHL [3, 4] . The histologic subtypes in most primary GI-NHL are mucosalassociated lymphoid tissue (MALT) lymphoma or highgrade B-cell lymphoma [5] [6] [7] [8] . GI-FL is rare, and the frequency of this entity accounts for 1%-3.6% of GI-NHL [8] [9] [10] . The diagnosis, prognosis, and treatment of GI-FL remain largely unknown because of its rare frequency. In this article, the clinical, biologic, and endoscopic characteristics, as well as the outcomes of these lymphomas are reviewed, based on the literature and our experience.
Clinical features
To our knowledge, 244 cases of primary GI-FL have been reported with precise descriptions in the English-language literature [2, 8, . The clinical features of 249 GI-FLs, including the 244 reported cases and 5 unpublished cases that we experienced, are summarized in Table 1 .
Demographic features
The median age of patients at diagnosis of GI-FL is 56 years (range, 26-81 years), similar to that of nodal FL [58, 59] . In several case series of GI-FL, a female predominance was observed [8, 11, 12] , but other case series have demonstrated an equal sex distribution in GI-FL [15] [16] [17] [18] . Sato et al. [18] , who reported the largest case series of GI-FL, described an equal sex distribution in GI-FL. Based on the available data of all reported cases, there is an equal sex distribution (122 females and 124 males), which is similar to the sex distribution of nodal FL.
In contrast to the geographic distribution of nodal FL [1] , of the 249 cases of GI-FL, almost 50% (120) are Japanese cases [8, 13, 14, 17, . This geographic predominance may be due to the higher frequency of endoscopic examination in Japan compared with that in other countries, because 50 (84.7%) of the 59 patients with GI-FL in Japan, whose clinical symptoms were available, presented with no symptoms or only vague GI symptoms, while only 29 (32.2%) of 90 patients from other countries were asymptomatic.
Clinical symptoms
In most of the asymptomatic patients with GI-FL, the lesions were incidentally detected during routine esophagogastroduodenoscopy (EGD). Of 150 patients whose clinical symptoms at presentation are described in the literature, 65 (43.3%) were asymptomatic and 14 (9.3%) complained of vague GI symptoms such as abdominal discomfort or heartburn.
Abdominal pain was present in 43 of 150 patients (28.7%). Symptoms of intestinal obstruction, such as nausea and vomiting, were present in 12 (8.0%) and symptoms of intestinal bleeding, such as tarry stool or hematochezia, were present in 9 (6.0%). Intestinal obstructions usually occurred in patients with small-intestinal lesions, whereas bleeding was observed mostly in patients with colorectal lesions (Table 2 ). In some cases, patients with GI-FL have a protein-losing enteropathy [16, 22, [40] [41] [42] [43] .
Clinical stage
In GI-FL, most cases are classified using the Ann Arbor staging system [60] or the Lugano staging classification of GI tract lymphoma, which is a modified version of the Ann Arbor staging system for GI-NHL [61] (Table 3) .
Whereas most patients with nodal FL have systemic disease (i.e., stage III or IV) at the time of diagnosis [62] , of 193 GI-FL patients with available clinical stage data, 128 (66.3%) were at stage I and 52 (26.9%) were at stage II. Bende et al. [45] and Takata et al. [63] have speculated that the low tendency of GI-FL to disseminate outside the GI tract indicates that it is a distinct entity that originates from local antigen-responsive B cells in the intestinal mucosa. Bende et al. [45] demonstrated that GI-FLs expressed alpha4beta7 integrin, a well-defined mucosal homing receptor not expressed in nodal FLs. In addition, GI-FL has a higher frequency of grade 1 lymphoma than nodal FL (see ''Histologic grading''). The higher ratio of localized disease in GI-FL, however, may be due to the definition of GI lymphoma rather than to different tumor cell origins, because cases with both intestinal and massive extraintestinal lesions are excluded from primary GI-FL (see ''Definition of primary GI lymphoma'').
On the other hand, GI-FL can involve regional lymph nodes even in cases in which the primary lesion involves only the mucosal or submucosal layer [8, 28, 33, 44, 46] . GI-FL tends to involve only regional lymph nodes, although it occasionally disseminates outside the GI tract and its regional lymph nodes. Yoshino et al. [8] have suggested that this discrepancy is likely a result of the intricate muscle layer structures around the ampulla of Vater, because most intramural FL with regional lymph node dissemination involves this location [8, 28, 33] .
Disease distribution in the GI tract GI-FL may infiltrate unifocally or multifocally, and disease distribution is very important for deciding therapy, i.e., radiation therapy may be effective for unifocal local diseases and rituximab therapy with or without chemotherapy may be required for multifocal diseases. A relatively large case series reported that GI-FL predominantly involved the duodenum, especially around the ampulla of Vater, or the terminal ileum unifocally. In the series reported by Sato et al. [18] , 40 of 52 cases of extranodal FL (a number of cases with GI-FL were not described) arose in the duodenum, and in another series reported by Shia et al. [15] , duodenal FL accounted for 10 of 26 cases of FL of the GI tract, while Le Brun et al. [11] reported that 55% of the lymphomas occurred in the small intestine, where they showed a predilection for the terminal ileum. Damaj et al. [12] reported that the most frequent site of involvement was the small intestine, with a predilection for the ileum and ileocecal region. Huang et al. [16] reported that the most frequent site was the ileum (7 of 13 cases; 54%), with 4 tumors in the terminal ileum. On the other hand, some cases of GI-FL have lesions resembling multiple lymphomatous polyposis (MLP). MLP is characterized by numerous polypoid lesions ( Fig. 1 ) involving long segments of the GI tract, and it is a very rare entity, accounting for 2% of primary GI lymphomas [22] . Although first recognized in the 19th century by Cruveilhier, [64] malignant lymphoma that presented as multiple small nodules affecting the long segment of the GI tract had been paid little attention until 1961 when Cornes referred to this disease entity as ''multiple lymphomatous polyposis'' [65] . MLP was initially considered to be a typical feature of mantle cell lymphoma (MCL) [66] , but later studies indicated that MLP comprised a heterogeneous group of neoplasms, including MCL, FL, and MALT lymphomas [20, 67] . Since Le Brun et al. [11] reported that 5 of 31 cases (16.1%) of GI-FL had a multiple polypoid appearance, Where there is both nodal involvement and penetration involving adjacent organs, the stage is denoted using both a subscript (1 or 2) and E, e.g., II 1 E (pancreas)
Stage IV = disseminated extranodal involvement, or a GI tract lesion with supradiaphragmatic nodal involvement several case series on GI-FL have demonstrated that 15.0%-46.2% of GI-FL has MLP aspects [12, 16, 18] . In these reports, however, the whole GI tract was not evaluated in all cases. Because MLP involves the long segment of the GI tract and is often discontinuous [23, 65] , the frequency of GI-FL cases with MLP may actually be higher than that in these reports. Two innovative methods to observe the entire small intestine were recently introduced: wireless capsule endoscopy (WCE) and double-balloon enteroscopy (DBE). Both modalities allow high-resolution visualization of the whole small intestine (see ''Endoscopic examination''). At present, there are 3 case series of GI-FL in which the whole GI tract was examined using EGD, colonoscopy, and DBE. In these reports, the proportion of GI-FL with involvement at two or more sites of the GI tract was much higher than that in previous reports on GI-FL. Nakamura et al. [14] reported that 4 of 5 cases (80%) of GI-FL presented with multiple polypoid lesions resembling MLP in long segments of the jejunum or the ileum. In a case series by Kodama et al. [13] , DBE showed new lesions in the jejunum or the ileum in 8 of 11 patients (73%) in whom GI-FL was detected in the duodenum with EGD. Higuchi et al. [32] reported that jejunoileal FL lesions were detected with DBE in 6 of 7 patients (85.7%) with FL in the duodenum. Data on the disease distribution of GI-FL, based on the English-language literature and our unpublished cases, are summarized in Table 4 . Before the introduction of WCE and DBE, it was reported that most GI-FLs were unifocal (176 of 216 cases; 81.5%) and the most frequent site was the duodenum (95 cases; 54.0%) followed by the ileum including the terminal ileum (28 cases; 15.9%). On the other hand, in 33 patients with GI-FL where the entire intestine was examined with endoscopy, including WCE or DBE, 24 patients (72.7%) suffered from GI-FL with multifocal involvement, and the proximal small intestine including the duodenum and the jejunum was the most frequent site of invasion.
Although there is only a small number of cases of GI-FL in which WCE or DBE was performed, the frequency of GI-FL with long segmental GI tract involvement appears to be much higher than previously reported. Further investigation with WCE or DBE will be useful for accurately evaluating the disease distribution of GI-FL.
Diagnosis
The diagnosis of primary GI-FL consists of two aspects. One is to diagnose FL as a clinicopathologic subset, and the other is to judge whether lymphoma arises from the GI tract or whether it involves the GI tract as a result of dissemination from the primary site.
Definition of primary GI lymphoma
It is not always possible to determine the primary site of origin of lymphoma involving the GI tract, especially in cases with both GI and extra-GI involvement. There are two possibilities of GI involvement of lymphoma cells. First, lymphoma arising from regions other than the GI tract presents in the GI tract with an advanced stage of generalized disease. Second, primary GI lymphomas can disseminate and involve lymph nodes or other extraintestinal sites. At present, there is no way to distinguish whether the GI tract is the primary site or a secondary site representing an advanced stage of FL involving the GI tract.
There are several definitions of primary GI lymphoma and at least two of them are widely used. One is the definition by Dawson et al. [68] put forth in 1961 that restricts GI lymphoma as a localized disease without involvement of peripheral or mediastinal lymph nodes, liver, or spleen. The other is the definition by Lewin et al. [9] , which extends to a wider range of presentations and requires that patients exhibit GI symptoms or a predominant lesion with or without extraintestinal lesions. In most case series of GI-FL, the definition by Lewin et al. was applied and cases with massive extraintestinal lesions were excluded from primary GI-FL [11, 12, [15] [16] [17] .
Endoscopic examination

Modality of endoscopic examination
Endoscopic examinations allow for direct observation and biopsy of the GI tract, and biopsy specimens can be subjected to morphologic evaluation as well as immunohistochemical evaluation and molecular analysis. This modality is essential for diagnosing lymphoma, defining the extent of bowel involvement, and assessing the efficacy of treatment. However, it is very difficult to observe the entire small intestine with conventional endoscopy, including EGD, colonoscopy, and push enteroscopy. The recent development of WCE and DBE has enabled observation of the entire GI tract. WCE, first reported by Iddan et al. [69] , transmits images at a rate of two frames per second for more than 8 h, permitting the acquisition of more than 50 000 images [70] . The DBE system developed by Yamamoto et al. [71] in 2003 enables deep insertion of an endoscope to the small intestine by preventing overstretching of the intestinal tract with an attachable balloon at its tip and a soft overtube with another balloon at the distal end [71] . These methods allow for detailed observation of the mucosa of the deep small intestine and have provided new data regarding the distribution of GI-FL (see ''Disease distribution in GI tract'').
WCE is a noninvasive outpatient procedure; sedation is unnecessary and there is no risk of exposure to X-rays. On the other hand, DBE can be used to obtain biopsy specimens of the small intestine far from the mouth or anus and to perform endoscopic therapeutic interventions, which cannot be done with WCE. Therefore, WCE appears to be suitable for screening examinations and for assessing treatment efficacy, but DBE is recommended for cases in which histologic evaluation is necessary or intestinal stenosis is suspected.
Characteristic endoscopic findings
For 183 of 249 cases of GI-FL, a precise description of the endoscopic findings is available, and these are summarized in Table 5 . In 95 of these cases, endoscopic findings represented small whitish polypoid, confluent or scattered lesions or nodules, with a 1-to 2-mm-diameter (Figs. 1, 2a, b), described as ''multiple polypoid lesions'', ''multiple whitish small polyps'', ''dense and numerous sessile polyps'', ''yellow-whitish multiple granules'', or ''multiple nodular lesions''. Magnifying endoscopic examination revealed that these whitish small nodules were enlarged and fused villi and that the mucosa of these lesions had a normal appearance, which was suggestive of a subepithelial or submucosal lesion (Fig. 3 ) [23, 25, 36, 38] . Endoscopic ultrasonography reveals thickening of the mucosal and submucosal layers of the intestinal wall with multiple hypoechoic granules corresponding to the lesions [19, 25, 26, 44] . These findings suggest that each granule is an enlarged neoplastic follicle that consists of lymphoma cells in the lamina propria, which has been confirmed with histologic examination (Fig. 4a-d) . Aggregation of such nodules can be unifocal or multifocal throughout the entire GI tract (see ''Disease distribution in the GI tract'') and is characteristic of lymphoid hyperplasia and low-grade B cell lymphoma, including MALT lymphoma with follicular colonization, FL, and MCL. In some cases, macroscopic findings alone are not sufficient to distinguish between these disease subsets [20] (Fig. 5) , and pathologic examinations, immunohistochemical staining, and molecular analysis are necessary in such cases. Because the prognoses for MALT lymphoma, FL, and MCL are quite different [20] , it is very important to establish a differential diagnosis of these diseases. Therefore, obtaining biopsy specimens for histopathologic evaluation, including immunohistochemical staining and molecular analysis, is strongly recommended when the above characteristic findings are observed. The second most common finding is a mass lesion with or without ulceration (38 cases). Mass lesions sometimes present with a submucosal tumor-like appearance (Figs. 6a,  b, 7a) . In approximately 50% of cases of GI-FL with a mass lesion, however, multiple nodular lesions are observed at other sites in the GI tract (Fig. 7b) . Therefore, in most cases of GI-FL, multiple nodular lesions might be observed in the early stage.
Regarding frequent endoscopic findings in each site of GI tract, endoscopy usually reveals multiple polypoid lesions in the duodenum, jejunum, ileum, and colon. Detailed macroscopic findings are available for only 2 of 13 cases reported as primary gastric FL [21, 37] . In both cases, the macroscopic appearance of FL was submucosal tumor-like (Fig. 6a, b ) and could not be distinguished from the other subtypes of GI lymphoma, especially diffuse large B-cell lymphoma, which is one of the most common types of high-grade gastric lymphoma. Rectal lesions of GI-FL sometimes present as a single elevated mass like a polyp [36] . GI-FL rarely involves the esophagus and there are only 3 cases in which an esophageal lesion was observed [20, 22] and in all cases the esophageal lesion presented as a part of MLP.
Pathology and biology GI tract and skin are reported to be the most common sites of primary extranodal FL [2] . Primary cutaneous FL is considered to be a distinct entity from nodal FL because of the lack of t(14;18)(q32;q21) and the relatively favorable response to treatment [72] [73] [74] [75] , although FL in this site shares some features with nodal FL, such as cell morphology and growth pattern. These findings raise the possibility that FL arising in the GI tract can be distinguished from FL normally found in lymph nodes as considered in cutaneous FL. In conclusion, the morphologic features, immunophenotype, and presence of t(14;18) (q32;q21) suggest that primary GI-FL may be more closely related to nodal FL than to cutaneous FL or other primary GI lymphoma, although some reports on GI-FL have emphasized the differences between GI-FL and nodal FL [18, 45, 63] .
Morphology
Microscopic findings The morphologic features of GI-FL cannot be distinguished from those of nodal FL [45] . In the typical GI-FL case, the follicles are approximately the same size as a mature germinal center, uniform in size, closely packed, and lacking a mantle zone, presenting in the lamina propria of the intestinal mucosa at the early stage ( Fig. 4a ) and transmural at an advanced stage. The centrocytes, which are usually less than twice the size of small lymphocytes and whose nuclei are irregular [76] , and centroblasts, which are usually three to four times the size of small lymphocytes and whose nuclei are round but may be irregular [76] , of GI-FL are identical to those of normal germinal centers. A starry-sky pattern with phagocytic histiocytes is usually absent in GI-FL [45] , as well as in nodal FL [76] .
In most cases of GI-FL, the tumor cells do not infiltrate and destroy the gland epithelium, i.e., there is no lymphoepithelial lesion, which is one of the characteristic findings of MALT lymphoma. Tzankov et al. [48] , however, reported a case of gastric FL in which a lymphoepithelial lesion was observed, and Takeshita et al. [77] reported that lymphoepithelial lesions occurred in 2 of 12 CD10-positive diffuse large-cell lymphomas of the stomach that had a germinal center B-cell phenotype. Thus, the presence of a lymphoepithelial lesion may not exclude the possibility of FL, especially in gastric lymphoma.
Histologic grading In most cases of GI-FL as well as nodal FL, FL is categorized into three grades based on the criteria of Berard and Mann [78] , according to the number of centroblasts (large nucleolated cells) per high-power field. In nodal FL, several studies suggest that this grading is a good predictor of prognosis [79, 80] , and grade 3b FL tends to behave similarly to de-novo diffuse large B-cell lymphoma, with earlier relapses and a shorter survival [81] . Frequencies of grade 1, grade 2, and grade 3 in GI-FL are 84.4%, 11.3%, and 4.3%, respectively (Table 6 ), while those of grade 1, grade 2, and grade 3 in nodal FL are 40%-60%, 25%-35%, and approximately 20%, respectively [76] . This may be one of the reasons why GI-FL tends to be detected at an earlier stage and have a better overall survival rate than nodal FL (see ''Clinical stage'' and ''Prognosis of GI-FL'').
Immunophenotype
In GI-FL, as well as nodal FL, tumor cells are positive for pan-B-cell antigens, including CD19, CD20, and CD22, and negative for CD5 and cyclin D1 [45] , which are characteristically expressed in MCL and small lymphocytic lymphoma/chronic lymphocytic leukemia [82] . Immunohistochemical staining for CD10 and bcl-2 is useful for distinguishing FL from lymphoid hyperplasia, MALT lymphoma, or MCL [76] . Both CD10 and bcl-2 are expressed in approximately 90% of cases of GI-FL in which expression of both CD10 and bcl-2 were evaluated (Table 7 ; Fig. 4c, d ), while normal germinal center cells express CD10 but not bcl-2 (Fig. 5d, e) . MCL expresses neither CD10 nor bcl-2, and MALT lymphoma is negative for CD10 and occasionally positive for bcl-2 [76] .
Bende et al. [45] demonstrated that GI-FL expressed alpha4beta7 integrin, a well-defined mucosal homing receptor, and surface IgA, in contrast to nodal FLs, and speculated that GI-FL is a distinct entity that originates from local antigen-responsive B cells in the intestinal mucosa. No other reports, however, have confirmed that GI-FL expresses alpha4beta7 integrin. In addition, only 1 of 23 other cases in which the surface immunoglobulin of tumor cells was examined expressed IgA, and GI-FL most often expressed surface IgM, followed by IgD (Table 7) [ 16, 19, 22, 34, 46, 47] , similar to nodal FL. Therefore, further evaluation is necessary to elucidate whether or not GI-FL has a different immunophenotype, including alpha4beta7 integrin and surface immunoglobulin, compared to nodal FL.
Genetic features
In 70%-95% of nodal FL, t(14;18)(q32;q21), which causes a fusion of BCL2 with the immunoglobulin heavy chain joining region and prevents the normal switching off of BCL2, is present [83] [84] [85] . On the other hand, most primary cutaneous FL lacks t(14;18)(q32;q21) [72] [73] [74] [75] . Thus, in cases of GI-FL, the presence of this chromosomal rearrangement is examined with Southern blotting, polymerase chain reaction (PCR) (Figs. 7c, 8 ), or fluorescence in situ hybridization (FISH) (Fig. 7d) .
Southern blotting, PCR, and FISH demonstrated the presence of an IgH/BCL2 rearrangement in 60%, 57.1%, and 72% of GI-FLs, respectively (Table 8) , the same frequency as that in nodal FL.
PCR analysis for GI-FL seems to be less sensitive than FISH analysis, as described for nodal FL [86] [87] [88] [89] . In all cases in which t(14;18)(q32;q21) was not detected by PCR analysis, the breakpoint used for diagnosis was a major break region (MBR) [90] , at which the breakpoint is located in only 50%-60% of nodal FL [86, 91] , and other breakpoints, including the minor cluster region (mcr), 3' BCL2, 5'mcr, and intermediate cluster region (icr) [92] [93] [94] [95] were not evaluated. Therefore, in such cases additional PCR analysis using primers for other BCL2 breakpoints or FISH analysis may be more sensitive.
FISH and PCR analysis can be performed on fresh, frozen, or fixed paraffin-embedded material [96] . In addition, FISH analysis can demonstrate IgH/BCL2 rearrangement regardless of the location of the BCL2 breakpoint and its probes do not require absolute sequence complementarity for detecting the rearrangement [96] . In both nodal FL [86] and GI-FL, FISH analysis seems to be superior to PCR analysis in detecting t(14;18)(q32;q21) ( Table 8) .
Taken together, the presence of t(14;18)(q32;q21) in GI-FL suggests that primary GI-FL is more closely related to nodal FL than cutaneous FL and demonstrates that the IgH/BCL2 rearrangement is useful for diagnosing not only nodal FL but also GI-FL, with equivocal morphologic and immunophenotypic findings. Given its superior diagnostic sensitivity, FISH should be considered as an initial diagnostic method to detect t(14;18)(q32;q21) or as an alternative method for cases that are negative with PCR, which is a less expensive and faster technique to perform than FISH. Therefore, for the diagnosis of GI-FL, biopsy specimens for fixation with formalin and for FISH or PCR analysis should be obtained for higher diagnostic sensitivity.
Takata et al. [63] reported that duodenal FL cells showed accumulation of somatic hypermutation and ongoing mutations in spite of the lack of activation-induced cytidine deaminase expression and their follicular dendritic cell network formation, which is similar to neoplastic marginal zone-like B cells. In addition, these authors demonstrated that duodenal FL had a restricted usage of variable region of immunoglobulin heavy chain gene (VH). Duodenal FL in their series had a higher usage of VH4 and VH5 than nodal FL, and VH4-34 and VH5-51 were detected in many of these cases. They speculated that these findings could indicate that the lymphoma cells are derived from B 
Staging
Accurate staging of GI-FL is important because durable remissions, and in some cases cures, can be achieved with surgical resection or external-beam radiotherapy of the affected area in patients with localized disease (see ''Gastrointestinal follicular lymphoma treatment'').
Staging procedures
Staging procedures for GI-FL are almost the same as those routinely used for nodal FL. In addition to a staging workup, however, including an accurate physical examination, complete hematologic and biochemical examinations, total-body computerized tomography (CT), and bone marrow aspirate and biopsy, evaluation of the whole GI tract using EGD, colonoscopy, and total enteroscopy (i.e., WCE or DBE) are necessary to determine GI-FL staging, because GI-FL often involves long segments of the GI tract (see ''Disease distribution in the GI tract'').
Recent advances in gastrointestinal follicular lymphoma staging
Fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) scanning has recently emerged as a major imaging modality for the staging and follow up of patients with lymphoma, especially aggressive lymphomas [97] [98] [99] . FDG-PET scanning has excellent sensitivity and specificity for staging in nodal FL as well, in contrast to other indolent lymphomas, including B-cell small-cell lymphocytic lymphoma, marginal zone lymphoma, and MCL [100] [101] [102] .
There are a few reports in which FDG-PET was performed for staging in GI-FL [24, 32, 37, 41, 44] . In 14 of 16 cases of FL of the small intestine, there were no obvious accumulations of 18F-FDG in the primary lesions. Focal 18F-FDG uptake in the primary site was observed in 1 case of gastric FL [37] and 2 cases of FL of the small intestine [32] . In all of these cases, the primary lesion formed a mass lesion. It is noteworthy that small mediastinal lymph node dissemination was detected with FDG-PET in one gastric FL case (Fig. 6c, arrowhead) [37] . In this case, the disseminated lesion above the diaphragm could not be detected with CT, which was performed before the FDG-PET examination. In another case of duodenal FL [24] , 18F-FDG accumulated in the mesenteric lymph nodes, whereas there was no obvious uptake in the primary site. Therefore, this modality may not be useful for evaluating the spread of the primary lesion, as Hoffman et al. [44] and Higuchi et al. [32] demonstrated, but the modality is useful for evaluating lymph node dissemination.
Prognosis in patients with gastrointestinal follicular lymphoma
Prognosis of GI-FL
The long-term clinical outcome of GI-FL remains unclear because there has been no analysis of a large populationbased registry of survival for patients with GI-FL. In 2 case series on long-term outcomes of patients with GI-FL, relapse-free median time or median relapse-free survival was similar to that for nodal FL [12, 15] . Shia et al. [15] reported a median relapse-free survival of 63 months in 25 GI-FL patients. Damaj et al. [12] reported a median time to progression of 37.5 months in 7 patients without any treatment and a median time to recurrence of the disease of 31 months in 18 patients with treatment.
On the other hand, based on all available data reported previously, GI-FL seems to have a better prognosis than nodal FL. There are only five reported cases in which the patients died of GI-FL, and, among 249 GI-FL patients, 3 patients died of another disease [12, 20, 22, 54] . In addition, the median relapse-free survival was 98 months in 96 patients with GI-FL (Fig. 9a ), which appears to be a more favorable outcome compared with that of nodal FL.
In GI-FL, the frequency of grade 1 lymphoma is much higher compared with that in nodal FL (see ''Histologic grading''), and most GI-FL presents as a localized disease at the time of diagnosis, while most nodal FL involves multiple sites when staging procedures are performed (see ''Clinical stage''). These features may indicate that GI-FL is a distinct entity from nodal FL, and is slower to progress.
There may be other reasons for the better prognosis of GI-FL compared with that of nodal FL. When lymphoma cells infiltrate not only the GI tract but also extraintestinal sites, e.g., peripheral or mediastinal lymph nodes, liver or spleen, most such cases, especially those with massive extraintestinal lesions, are excluded from primary GI-FL [11, 12, [15] [16] [17] because of the inability to distinguish between primary GI-FL with extraintestinal invasion and secondary GI-FL as a result of dissemination from another site (see ''Definition of primary GI lymphoma''). Second, there are only a few GI-FL patients with a long-term follow up, because of its rarity. The median follow-up duration of the reported cases of GI-FL is only 24.5 months, while the median follow up was more than 50 months in most studies of the long-term clinical outcome of nodal FL [103] [104] [105] .
Grade 1 GI-FL tends to have a better relapse-free survival than grade 2 GI-FL, but the prognosis for grade 3 lymphoma is unclear because of its rarity. Relapse-free survival of grade 1, grade 2, and grade 3 is 61.6% at 180 months (n = 48), 41.7% at 112 months (n = 13), and 100% at 108 months (n = 3), respectively (Fig. 9b) . The difference in overall survival between each grade is also unknown, as only 5 patients died of GI-FL and 3 died of other diseases, based on the data in the available literature [12, 20, 22, 54] .
To compare the prognosis between localized GI-FLs (i.e., stage I or II) and systemic ones (i.e., stage III or IV) is difficult, because only 13 of 193 GI-FL patients (6.7%) with available clinical stage data had a systemic disease.
Recurrence after achieving complete remission in GI-FL Of 249 patients with GI-FL, 106 achieved complete remission with various therapies (see ''Gastrointestinal follicular lymphoma treatment''). Of those, FL relapsed in 16 cases from 1 to 98 months after achieving of complete remission [12, [15] [16] [17] 47] . Details of relapsed cases are summarized in Table 9 . Median time to recurrence was 44.5 months. Initial treatments to induce remission were surgery (4 cases), radiation (1 case), chemotherapy (4 cases), radiation plus chemotherapy (2 cases), surgery plus chemotherapy (4 cases), and radiation plus surgery following chemotherapy (1 case). It is noteworthy that FL relapsed outside the GI tract, including in extraabdominal lymph nodes, the spleen, and tonsils, in about 50% of the recurrent cases [15] [16] [17] . Therefore, not only evaluation of the GI tract using endoscopy and abdominal CT scan but also whole-body evaluation, including gallium scintigram or FDG-PET, should be performed for follow-up studies after the achieving of complete remission. To screen for extraabdominal relapse, FDG-PET rather than gallium scintigraphy is recommended because of its sensitivity [100] (see ''Recent advances in gastrointestinal follicular lymphoma staging'').
Gastrointestinal follicular lymphoma treatment
Management of GI-FL is controversial, mainly because of its rarity. Damaj et al. [12] reported that there was no significant difference in the prognosis between patients without treatment and those with treatment, as in nodal FL [106] [107] [108] . Therefore, a ''watch and wait policy'' has been adopted in some asymptomatic patients with GI-FL [13, 15, 17, 18, 20, 23, 54, 55] . In other patients, surgery, radiotherapy, chemotherapy, monoclonal antibody therapy, or a combination of these therapies is performed. In addition, antibiotic therapy has been tried in several patients with GI-FL [7, 17-19, 24, 25, 34, 50] , based on the established efficacy of antibiotics in patients with other indolent GI lymphomas, such as gastric MALT lymphoma or immunoproliferative small intestinal disease (IPSID). GI-FL treatments and responses are summarized in Table 10 .
Conventional therapies
Patients with GI-FL have been treated with surgery, radiotherapy, chemotherapy, or a combination of these therapies. To compare the effect of each therapy with another is difficult, however, because the number of patients receiving each type of treatment is very small and the background of the cases, including clinical stage and duration of follow up, varies. In general, a complete response was achieved in most patients regardless of treatment modality, reflecting the indolent nature of GI-FL Fig. 9 a Kaplan-Meier plot of relapse-free survival after achieving complete remission in patients with GI-FL. b Relapse-free survival according to histologic grade. Relapse-free survival of grade 1, grade 2, and grade 3 was 61.6% at 180 months (n = 48), 41.7% at 112 months (n = 13), and 100% at 108 months (n = 3), respectively (Table 10 ) (see ''Prognosis in patients with gastrointestinal follicular lymphoma''). Chemotherapy for GI-FL is performed based on the therapeutic regimens of nodal FL, especially in patients with systemic disease or widespread GI tract involvement.
Rituximab-containing regimen
After the introduction of therapies using the monoclonal antibody against CD20, rituximab, several randomized studies demonstrated that this therapeutic modality, combined with conventional therapies, improved not only the complete response rate and the duration of the response but also the overall survival rate of nodal FL [109] [110] [111] . In addition, in GI-FL, immunotherapy using rituximab with or without chemotherapy has been performed [7, 13, 16-18, 20, 24, 28, 41, 42, 56] , although the efficacy of therapy including rituximab has not been compared with that of conventional therapy alone. There seems to be no difference in the response of GI-FL between therapeutic regimens containing rituximab and conventional therapy at present, which may be due to the disease rarity and the favorable nature of the disease (Table 10) .
Antibiotic therapy
Growing evidence indicates that some subtypes of marginal zone lymphomas are associated with chronic antigen stimulation by microbial pathogens and that therapy with antibiotics is effective in marginal zone lymphoma of MALT type, including gastric MALT lymphoma and IPSID.
Several studies have revealed a close association of infection with H. pylori and gastric MALT lymphoma [112] [113] [114] [115] , and the eradication of H. pylori infection results in lymphoma remission in patients with low-grade MALT lymphoma localized in the stomach [116] [117] [118] [119] [120] [121] [122] .
IPSID, which is also called ''Mediterranean lymphoma'' or ''alpha heavy chain disease'' [123] , is a variant of MALT lymphoma in the small intestine. Early-stage IPSID responds to antibiotics such as tetracycline, ampicillin, or metronidazole [124] . Recently Lecuit et al. [125] have reported that IPSID is associated with Campylobacter jejuni.
Also in GI-FL, some patients were treated with antibiotics using an H. pylori eradication regimen, because H. pylori was detected in the stomach or a diagnosis of MALT lymphoma was made at first. Most GI-FL lesions, however, were unchanged or progressed despite the administration of antibiotic agents [17, 18, 24, 25, 50] . The fact that antibiotic therapy is ineffective for most patients with GI-FL may indicate that the neoplastic follicles of GI-FL are not composed of antigen-driven cells, different from MALT lymphoma [126] .
In several patients with GI-FL, however, regression of GI-FL was noted after antibiotic treatment [14, 19, 34] . Toyoda et al. reported a case of duodenal FL that regressed 12 months after eradication of H. pylori although the immunophenotype of the tumor cells was CD10-and bcl-2?, which is characteristic of MALT lymphoma rather than FL [19] . Nakamura et al. [14] described a patient who showed regression of GI-FL at 15 months after antibiotic treatment, and Nomura et al. [34] reported that duodenal FL regressed at 12 months after antibiotic therapy. These cases may suggest that tumor cell growth depends on stimulation with antigens originating from the gut lumen via B-cell receptors on the tumor cells in some cases of GI-FL, as Bende et al. [45] and Takata et al. [63] have speculated.
Conclusion
Although GI-FL is generally considered to be a rare entity, the number of reported cases of GI-FL is increasing. A consensus regarding the management of this disorder, however, has not yet been established. Irrespective of the specific therapy, the overall survival of GI-FL appears to be good. Little is known about long-term clinical outcome of GI-FL, especially since treatment with rituximab was introduced. Therefore, further studies are necessary to evaluate how rituximab changes the clinical outcome of GI-FL. Accurate evaluation of the distribution of the disease, however, is necessary for deciding on the treatment modality. WCE and DBE, which provide detailed information about the mucosa of the whole small intestine, are useful for localizing GI-FL because of the potential multifocal involvement of the GI tract in many cases. GI-FL tends to be localized in the GI tract and regional lymph nodes at diagnosis, whereas extraabdominal relapse is observed in about 50% of recurrent cases. Accordingly, endoscopic examination throughout the entire GI tract and whole-body evaluation with FDG-PET is necessary for staging and follow-up studies.
